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Grb7 has potential importance in the progression of cancer. We have previously identified a novel peptide that binds to the SH2
domain of Grb7 and inhibits its association with several different receptor tyrosine kinases. We have synthesised the Grb7 peptide,
G7-18NATE, with two different cell penetrating peptides, Penetratin and Tat. In this study, we have shown that both Penetratin- and
Tat-conjugated G7-18NATE peptides are able to inhibit the proliferation of SK-BR-3, ZR-75-30, MDA-MB-361 and MDA-MB-231
breast cancer cells. There was no significant effects on breast cancer MCF-7cells, non-malignant MCF 10A or 3T3 cells. In addition,
there was no significant inhibition of proliferation by Penetratin or Tat alone or by their conjugates with arbitrary peptide sequence in
any of the cell lines tested. We determined the EC50 of G7-18NATE-P peptide for SK-BR-3 cell proliferation to be 7.663 10
 6 M.
Co-treatment of G7-18NATE-P peptide plus Doxorubicin in SK-BR-3 breast cancer cells resulted in an additional inhibition
of proliferation, resulting in 56 and 84% decreases in the Doxorubicin EC50 value in the presence of 5 10
 6 and 1.0 10
 5 M
G7-18NATE-P peptide, respectively. Importantly, the co-treatment with Doxorubicin and the delivery peptide did not change the
Doxorubicin EC50. Since Grb7 associates with ErbB2, we assessed whether the peptide inhibitor would have a combined effect with
a molecule that targets ErbB2, Herceptin. Co-treatment of Herceptin plus 1.0 10
 5 M G7-18NATE-P peptide in SK-BR-3 cells
resulted in a 46% decrease in the Herceptin EC50 value and no decrease following the co-treatment with Herceptin and penetratin
alone. This Grb7 peptide has potential to be developed as a therapeutic agent alone, in combination with traditional chemotherapy,
or in combination with other targeting molecules.
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Most chemotherapeutic drugs that are being used presently have
little selectivity for cancer cells and target all cells that are rapidly
dividing. This leads to increased toxicity against normal cells that
have enhanced proliferation, such as bone marrow, gastrointen-
stinal tract and hair follicles. Since side effects occur as a result of
these toxicities to normal tissue, anti-cancer drugs are often given
at suboptimal doses, resulting in common failure of the therapy.
There are newer drugs being developed against specific molecules
that play a key role in the proliferative, migratory and invasive
properties of cancer cells.
Many groups have developed growth-inhibitor monoclonal
antibodies that target the receptor tyrosine kinase (RTK) ErbB2
(Drebin et al, 1985; Hudziak et al, 1989; Harwerth et al, 1993; Lewis
et al, 1996). In September 1998, a major clinical milestone in the
field of targeted therapeutics was reached when the humanised
4D5 antibody, known as trastuzumab (Herceptin), was approved
by the Food and Drug Administration for the treatment of breast
cancer (Baselga et al, 1996; Slamon and Pegram, 2001). Herceptin
binds to the extracellular domain of ErbB2 and induces regression
of ErbB2-overexpressing breast cancers (Baselga et al, 1996).
ErbB2 is an attractive target since it is overexpressed on cancer
cells of a number of different histological types and associated with
the malignant phenotype. Blocking the function of ErbB2 leads
to inhibition of proliferation of cancer cells as demonstrated in
preclinical (Hudziak et al, 1989; Fendly et al, 1990) and clinical
studies (Baselga et al, 1996; Slamon and Pegram, 2001).
There are a number of clinical trials underway to evaluate the
combination treatment of Herceptin with several different
chemotherapeutic agents. Herceptin in combination with cisplatin,
paclitaxel, docetaxel, gemcitabine and vinorelbine have shown
promising clinical results (Yeon and Pegram, 2005; Nahta and
Esteva, 2006). The theory is that combining Herceptin with other
biological targeting agents may increase the extent of the patient
response. Some of the newer novel combinations include
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sHerceptin plus anti-EGFR tyrosine kinase inhibitor gefitinib
(Iressa), lapatinib (Tarceva), a combined EGFR/ErbB2 inhibitor
lapatinib (GW572016), cyclin-dependent kinase inhibitor flavopir-
idol, VEGF inhibitor becacizumab (Avastin) and Interleukin
inhibitors (Yeon and Pegram, 2005; Nahta and Esteva, 2006).
Grb7 is an adapter-type signalling protein, which is recruited via
its SH2 domain to a variety of RTKs, including ErbB2. Grb7 is
an especially promising cancer target as the encoding gene maps
closely to the ErbB2 gene on human chromosome 17q12 and is
found co-amplified and overexpressed in a subset of breast,
esophageal and gastric cancers (Stein et al, 1994; Kishi et al, 1997;
Tanaka et al, 1997; Fiddes et al, 1998; Kauraniemi et al, 2001; Varis
et al, 2002; Andrechek et al, 2003; Bieche et al, 2003). Analysis of
chromosome 17q12 in a variety of different breast cancer cell lines
Grb7 was found to have a high DNA copy number with a high level
of ErbB2 co-expression (Kauraniemi et al, 2001). Similar findings
were observed in ErbB2-induced mammary tumours from
transgenic mice (Andrechek et al, 2003). In addition, Grb7
expression had the strongest association with ErbB2 expression
in 54 primary breast tumours analysed by real-time quantitative
RT-PCR (Bieche et al, 2003). Co-expression of Grb7 with ErbB2
was detected in 31% of esophageal carcinomas and was
significantly correlated with extramucosal tumour invasion
(Tanaka et al, 1997). Moreover, Grb7 is co-expressed with ErbB3
and ErbB4, which are known to heterodimerise with ErbB2, in a
subgroup of human breast cancer cell lines. These studies, both
in vitro and in vivo, showing Grb7 being over-expressed or co-
overexpressed with ErbB2 emphasises the potential importance of
Grb7 in cancer progression.
In our previous studies, we discovered a novel non-phosphory-
lated peptide that binds to the SH2 domain of Grb7. This peptide
was a disulfide-bridged cyclic peptide generated by filamentous
phage display (Pero et al, 2002). This peptide contained 10 amino
acids flanked by two terminal cysteines to create a cyclic peptide
through disulfide linkage. The free peptide was synthesised
as a redox stable thioether-bridged analog, referred to as G7-
18NATE (Pero et al, 2002). G7-18NATE was found to specifically
bind to the SH2 domain of Grb7 and inhibit the association of
Grb7 protein with various RTKs (Pero et al, 2002; Tanaka et al,
2006). Since Grb7 is an intracellular target, we made G7-18NATE
peptide cell permeable by adding the penetratin peptide sequence,
referred to as G7-18NATE-P. Penetratin is a peptide derived from
the Drosophila transcription factor Antennapedia that mediates
rapid cellular delivery of proteins and peptides (Deshayes et al,
2005). We have shown previously that the cell permeable G7-
18NATE-P peptide is able to successfully translocate across the cell
membrane and significantly inhibited cell migration and perito-
neal metastasis in a pancreatic cancer mouse model (Tanaka et al,
2006). In the present study we also tested G7-18NATE conjugated
to the Tat cell penetrating peptide. Tat is derived from the
transcription factor protein of HIV-1 and known to deliver
proteins and peptides across the cell membrane (Deshayes et al,
2005).
Since ErbB2 has a role in proliferation of breast cancer cells and
Grb7 associates with ErbB2, we are interested in looking at the
effects of the Grb7 targeting peptide G7-18NATE-P on prolifera-
tion on a variety of different breast cancer cell lines. In addition,
we have studied the effects of treating cancer cells with G7-
18NATE-P peptide in combination with the chemotherapeutic
agent Doxorubicin and Herceptin.
METHODS
Peptide synthesis
Peptides were synthesised by the University of Vermont Protein
Core Facility. Thioether-cyclised peptides were synthesised ac-
cording to methodologies described previously (Pero et al, 2002).
Briefly, the peptides were synthesised on a PAL amide resin using
standard solid phase Fmoc chemistry-based protocols. The resin-
bound side chain protected peptides were N-terminally chloro-
acetylated with in situ-generated chloroacetic anhydride. The
peptides were removed from the resin and fully deprotected with
96:2:2 trifluoroacetic acid/triisopropylsilane/water. The crude
peptides were cyclised by intramolecular nucleophilic displace-
ment of the N-terminal chloro group by the C-terminal cysteine
side chain thiol functionality in an aqueous solution (0.1mmol of
peptide in 120ml of water) maintained at pH 8–8.5 with
triethylamine at room temperature for 6h. The peptides were
purified by reverse phase high-pressure liquid chromatography in
water/acetonitrile (0.05% trifluoroacetic acid) gradient. The purity
of the peptides was confirmed on a Shimadzu analytical high-
pressure liquid chromatography system (Shimadzu Corporation;
Kyoto, Japan). The identity of the peptides was determined using
an ABI Voyager DE-Pro Matrix Assisted Laser-desorption Ionisa-
tion instrument (Applied Biosystems; Foster City, CA, USA) under
positive ionisation and in reflectron mode. All samples were run
using a matrix of 10mgml
 1 alpha-cyano-4-hydroxycinnamic acid
vacuum dried from a solution of 1:1 acetonitrile buffered to 0.1%
trifluoroacetic acid. The peptides amino acid compositions are
listed in Table 1. In this study, we synthesised G7-18NATE peptide
with two different cell delivery peptides, Penetratin (referred to as
G7-18NATE-P) and Tat (referred to as G7-18NATE-T) (Table 1).
Additional control peptides were also synthesised; these include
Penetratin and Tat alone, as well as arbitrary peptides of the same
length with a thioether linkage conjugated to Penetratin (referred
to as NegCtrl-P) and Tat (referred to as NegCtrl-T), to mimic the
same structure as the G7-18NATE-conjugated peptides.
Cell culture
Human breast cancer cell lines SK-BR-3, MDA-MB-231, MDA-MB-
361, ZR-75-30, MCF-7, non-malignant human mammary epithelial
MCF 10A and mouse fibroblast 3T3 cell lines were all obtained
from American Type Culture Collection (ATCC; Manassas, VA,
USA). All cells were grown according to ATCC instructions except
MDA-MB-231 and MDA-MB-361 were grown in Dulbecco’s
Modified Eagles Medium (ATCC)þ10% fetal bovine serum
(ATCC) and MCF-7 cells were grown in Dulbecco’s Modified
Eagles Medium without phenol red (Mediatech, Herndon, VA,
USA). All cell lines were grown at 371Ca t5 %C O 2.
Table 1 Sequence and names of G7-18NATE peptides and negative control peptides
G7-18NATE-Penetratin (G7-18NATE-P) WFEGYDNTFPC*RQIKIWFQNRRMKWKK
G7-18NATE-Tat (G7-18NATE-T) WFEGYDNTFPC*YGRKKRRQRRR
Negative control penetratin (NegCtrl-P) RQAVSIAQASC*RQIKIWFQNRRMKWKK
Negative control Tat (NegCtrl-T) RQAVSIAQASC*YGRKKRRQRRR
Penetratin RQIKIWFQNRRMKWKK
Tat YGRKKRRQRRR
*Cysteine that creates the thioether linkage with the N-terminal residue.
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Proliferation was quantified using the BrdU chemiluminescent cell
proliferation ELISA (Roche Applied Science; Indianapolis, IN,
USA) following manufacturer’s instructions. The 96-well white
tissue culture-treated plates (Corning; Acton, MA, USA) were
seeded with 1 10
4 cells per well and allowed to adhere for 24h.
Cells were washed three times in Hank’s Balanced Salt Solution
and shifted to serum-free medium overnight. The next day, cells
were treated with different peptides, trastuzumab (Herceptin,
Genentech, South San Francisco, CA, USA), and/or Doxorubicin
(Sigma; St Louis, MO) and incubated at 371C, 5% CO2 for 8h. After
the 8h incubation, the BrdU labelling reagent and a second dose of
peptide were added to the cells and incubated for an additional
16h at 371C, 5% CO2. Chemiluminescent signals (rlu/s) were
detected on the GloRunner luminometer (Turner Biosystems,
Sunnyvale, CA, USA). Percentage of inhibition was calculated as
follows: 100 (treated rlu/sCuntreated rlu/s) 100. Each proli-
feration experiment was carried out at least twice with triplicate or
quadruplicate treatments. The results are described as mean7s.d.
of multiple experiments. EC50 values were determined with
nonlinear regression analysis using the Prism software version
4.03 for Windows (GraphPad Software, San Diego, CA, USA).
RESULTS
Cell permeable G7-18NATE peptides inhibit proliferation
of breast cancer cells
Using a BrdU-based cell proliferation ELISA, the effect of G7-
18NATE-P peptide has been evaluated on the proliferation of the
SK-BR-3 breast cancer cells. We found significant inhibition of
proliferation on SK-BR-3 breast cancer cells treated with the Grb7
targeting peptide, G7-18NATE-P. Figure 1 demonstrates this
inhibitory response of G7-18NATE-P with an EC50 at 7.3 10
 6–
8.0 10
 6 M (R
2¼0.9903).
In addition to the ErbB2 and Grb7 overexpressing SK-BR-3 cells,
we were interested in evaluating the effects of G7-18NATE-P on a
variety of different cells; including two additional overexpressing
cancer cell lines, ZR-75-30 and MDA-MB-361, two non-over-
expressing cell lines, MCF-7 and MDA-MB-231, and two non-
malignant cell lines, breast epithelial MCF 10A cells and fibroblast
3T3 cells. Figure 2A demonstrates that 1.0 10
 5 M G7-18NATE-P
inhibits 78% of SK-BR-3, 75% of MDA-MB-361 and 83% of
MDA-MB-231 cell proliferation. There was slightly less but still
significant inhibition for ZR-75-30 cells, which was measured at
54% inhibition of cell proliferation as compared to untreated cells.
The MDA-MB-231 is the only breast cancer cell line tested that was
found to be sensitive to G7-18NATE-P without overexpression of
Grb7. There is no significant inhibition found in the non-
overexpressing breast cancer cells line MCF-7 or non-malignant
cell lines MCF 10A and 3T3. Moreover, there was no significant
inhibition of proliferation by penetratin alone or by NegCtrl-P
peptide in any of the cell lines tested (Figure 2A).
To demonstrate that the anti-proliferation effect was a result of
the G7-18NATE peptide and not associated with delivery peptide,
we tested G7-18NATE conjugated to Tat. Although the effective
concentration of the Tat-conjugated G7-18NATE peptide was
higher (5.0 10
 5 M), we found similar inhibition of proliferation
in the SK-BR-3, ZR-75-30, MDA-MB-361 and MDA-MB-231 cells
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EC50 = 7.3×10−6 to 8.0×10−6 M
Figure 1 SK-BR-3 cells treated with varying concentrations of G7-
18NATE-P to determine EC50. Proliferation assays performed using a
chemiluminescent BrdU assay. SK-BR-3 breast cancer cells treated with 0 M
to 5 10
 5 M,a t5  10
 6 M increments. EC50 values were determined
with nonlinear regression analysis.
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Figure 2 Effects of G7-18NATE-P and G7-18NATE-T peptides on the
growth of breast cancer cells and non-malignant cells. Proliferation assays
performed using a chemiluminescent BrdU assay. Breast cancer cells tested
include SK-BR-3, ZR-75-30, MDA-MB-361, MDA-MB-231 and MCF-7. The
non-malignant human breast cells MCF10 A and mouse fibroblast 3T3 cells
were also tested. (A) Cells treated with 1.0 10
 5 M G7-18NATE-P,
NegCtrl-P or Penetratin alone. (B) Cells treated with 5 10
 5 M G7-
18NATE-T, NegCtrl-T or Tat alone. Sequence of peptides listed in Table 1.
Each proliferation experiment was carried out at least twice with triplicate
or quadruplicate treatments. Values represent the mean7s.d. of multiple
experiments, expressed as a percentage of the growth relative to untreated
controls.
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(Figure 2B). We found G7-18NATE-T peptide inhibited 88% SK-
BR-3, 86% ZR-75-30, 64% MDA-MB-361 and 98% MDA-MB-231
cell proliferation. There was no significant inhibition by Tat
peptide alone or Tat conjugated to the arbitrary negative control
peptide. This series of experiments demonstrates that the G7-
18NATE-conjugated peptides are able to significantly inhibit the
proliferation of several different breast cancer cells.
Cell permeable G7-18NATE peptides have a cooperative
effect with Doxorubicin and Herceptin
SK-BR-3 breast cancer cells were treated with Doxorubicin alone
or along with G7-18NATE-P peptide. Using non-linear regression
analysis, the EC50 value was determined for Doxorubicin-treated
SK-BR-3 cells to be 1.2 10
 6 M. Co-treatment of Doxorubicin plus
G7-18NATE-P peptide resulted in an additional inhibition of
proliferation (Figure 3). There was a 56 and 84% lowering of the
Doxorubicin EC50 value with 5 10
 6 and 1 10
 5 M G7-18NATE-
P peptide, respectively. Co-treatment with Doxorubicin and the
delivery peptide did not change the Doxorubicin EC50 (Table 2).
We found similar results with cells treated with Doxorubicin and
the Tat-conjugated G7-18NATE peptide (data not shown). This
shows that the treatment with G7-18NATE-P increased Doxo-
rubicin-mediated inhibition of cell growth.
To assess whether the peptide inhibitor would have a combined
effect with a molecule that targets ErbB2, we tested G7-18NATE-P
with Herceptin. SK-BR-3 breast cancer cells were treated with
Herceptin alone or along with G7-18NATE-P peptide followed by
BrdU analysis to measure cell proliferation. Using non-linear
regression analysis, the EC50 value was determined for Herceptin
to be 9.6 10
 6 M. Co-treatment of Herceptin plus 1.0 10
 5 M G7-
18NATE-P peptide resulted in a 46% decrease in the Herceptin
EC50 value (Figure 4). Similar results were obtained with cells
treated with Herceptin and the Tat-conjugated G7-18NATE
peptide (data not shown). We found no decrease of Herceptin
EC50 following co-treatment with Herceptin and penetratin alone
(Table 3). This series of experiments demonstrates that the Grb7
targeting peptide cooperatively inhibits the proliferation of SK-BR-
3 breast cancer cells with Doxorubicin and Herceptin.
DISCUSSION
Breast cancer is the second leading cause of cancer death in the
United States, affecting approximately one in eight women over the
course of their lifetime (Ries et al, 2005). Tumour size, grade,
stage, estrogen receptor expression and lymph node involvement
have been the markers used to select the course of therapy. With
the recent FDA approval of Herceptin, ErbB2 expression is a key
marker being identified in patients. ErbB2 positive patients being
treated with Herceptin along with chemotherapy have shown
prolonged survival rates. Despite these advances, the clinical
benefit of Herceptin is compromised by the fact that not all ErbB2-
overexpressing cancers respond clinically to the treatment and
some cancers develop resistance to this molecularly targeted drug
after initial response. It will be important to identify additional
targets for molecularly directed therapies to treat a greater number
of patients.
Grb7 is an SH2 containing adapter protein, which is known to
associate with several tumour-related molecules (Pero et al, 2003).
The importance of Grb7 in tumour progression has been suggested
by several studies (Tanaka et al, 1997, 1998, 2000; Han and Guan,
1999). Downregulating Grb7 either by anti-sense or siRNA
technology has shown to inhibit the invasive (Tanaka et al,
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Figure 3 Effects of combined treatment with G7-18NATE-P and
Doxorubicin on SK-BR-3 breast cancer cells. Proliferation assays performed
using a chemiluminescent BrdU assay. SK-BR-3 breast cancer cells treated
with 5.0 10
 6 and 1.0 10
 5 M G7-18NATE-P peptide with varying
concentrations of Doxorubicin (1.6 10
 7– 6.3 10
 6 M). Values repre-
sent the mean (n¼3)7s.d. In certain cases, the error bars are smaller than
the symbols, therefore they are not visible. EC50 values were determined
with nonlinear regression analysis.
Table 2 EC50 values of Doxorubicin-treated SK-BR-3 cells with and without peptides
Doxorubicin
Doxorubicin+5.0 10
 6 M
G7-18NATE-P
Doxorubicin+1 10
 5 M
G7-18NATE-P
Doxorubicin+5.0 10
 6 M
Penetratin
Doxorubicin+1 10
 5 M
Penetratin
Best fit 1.2 10
 6 5.2 10
 7 1.9 10
 7 1.0 10
 6 1.2 10
 6
95% confidence
interval
9.7 10
 7–
1.5 10
 6
3.9 10
 7– 7.1 10
 7 1.5 10
 7– 2.4 10
 7 9.6 10
 7–1.1 10
 6 1.0 10
 6–1.4 10
 6
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Figure 4 Effects of combined treatment with G7-18NATE-P and
Herceptin on SK-BR-3 breast cancer cells. Proliferation assays performed
using a chemiluminescent BrdU assay. SK-BR-3 breast cancer cells treated
with 1.0 10
 5 M G7-18NATE-P peptide with varying concentrations
of Herceptin (1 10
 6–3 10
 5 M). Values represent the mean (n¼4)
7s.d. In certain cases the error bars are smaller than the symbols, therefore
they are not visible. EC50 values were determined with nonlinear regression
analysis.
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cells. Another promising feature of Grb7 as a tumour target is its
limited tissue distribution, which is unlike that of many other SH2
domain-containing proteins which are ubiquitously expressed
(Margolis, 1994). Having limited tissue distribution is advanta-
geous for targeting therapeutics to cancer cells.
In this study, we have shown that cell permeable Grb7 binding
peptides inhibit the proliferation of several different breast cancer
cells. We found that G7-18NATE conjugated to Penetratin and Tat
has the same profile of inhibition on breast cancer cell
proliferation. However, the effective concentration for the Tat-
conjugated peptide was higher than the conjugated peptide, which
may be due to efficiency of translocation resulting from differences
in the mechanism of action of the two penetrating peptides.
Inhibition was observed in the SK-BR-3, ZR-75-30, MDA-MB-361
and MDA-MB-231 breast cancer cells. The observation of Grb7
peptide-induced inhibition of MDA-MB-231 cells, which do not
overexpress Grb7, demonstrates the peptide does not essentially
require Grb7 overexpression and may utilise some other mecha-
nism of inhibition in certain cell types. This type of phenomenon
has also been observed with Herceptin. Menendez et al (2006)
found Herceptin to inhibit certain breast cancer cells that do not
overexpress ErbB2 but do overexpress heregulin. Although MDA-
MB-231 does not overexpress ErbB2 or Grb7, it does overexpress
heregulin and promotes tumourigenicity and metastasis of breast
cancer cells (Aguilar and Slamon, 2001). Interestingly, the Grb7
peptide inhibits MDA-MB-231 cells and not MCF-7, which does
not overexpress heregulin, suggests there may be a correlation
between Grb7 peptide-induced response and heregulin over-
expression. Additional experiments will be required to understand
the mechanism of action for our Grb7 peptide.
Although we see dramatic inhibition of the proliferation on
breast cancer cells following G7-18NATE peptide treatment, we
have not been able to detect changes in phosphorylation of ERK or
AKT, two known molecules that have a role in cell survival
downstream of ErbB2. We have shown previously that the G7-
18NATE peptide inhibits the association of Grb7 with the ErbB
family of tyrosine kinases (Pero et al, 2002) and focal adhesion
kinase (Tanaka et al, 2006). The signal transduction pathway for
Grb7 has not been identified clearly. Therefore, probing into
multiple signalling pathways will be necessary to determine the
pathway that G7-18NATE peptide is invading.
In this study, we have also shown that the Grb7 peptide inhibitor
enhanced the inhibitory effect on SK-BR-3 proliferation when
treated with Doxorubicin. The peptide was able to significantly
reduce the EC50 of Doxorubicin. Most chemotherapeutic drugs are
given at suboptimal doses to minimise undesired side effects.
Combining chemotherapy with molecules, such as our Grb7
peptide, may have great potential at effectively killing the cancer
cells and minimising toxicity. In our recent study we have shown
that the Grb7 peptide inhibitor had low toxicity in mice (Tanaka
et al, 2006). In addition, this peptide is non-phosphorylated, which
may have an advantage of stability of other SH2 targeting peptides
that possess a highly charged phosphate group. When phosphate
groups are attached to a macromolecule, the ability of the
compound to enter cells is reduced, and the phosphorylated
compound is instable in vivo because of the presence of
endogenous phosphatases.
Since Grb7 associates with many oncogenic protein tyrosine
kinases, such as EGFR (Margolis et al, 1992), ErbB2 (Stein et al,
1994), Erbb3 (Fiddes et al, 1998) and ErbB4 (Fiddes et al, 1998),
combination therapy with protein tyrosine kinase targeting agents
and the Grb7 peptide inhibitor may be a novel therapeutic
intervention. Here we show that the Grb7 peptide in combination
with Herceptin treatment enhances the inhibitory effect on SK-BR-
3 proliferation. It is also worth noting that the Grb7 peptide is able
to effectively inhibit the ErbB2 and Grb7 overexpressing MDA-
MB-361 cells, which has been described previously as Herceptin
resistant (Yakes et al, 2002). In conclusion, this Grb7 inhibitory
peptide has potential to be developed as a therapeutic agent alone,
in combination with traditional chemotherapy, or in combination
with other targeting molecules for the treatment of cancer.
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